Therapy Detail

Therapy Name Exemestane + GS-5829
Therapy Description

Limited information is currently available GS-5829, a putative BET inhibitor (Jun, 2016).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Exemestane Aromasin Aromatase Inhibitor 3 Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary).
GS-5829 BET Inhibitor (Pan) 25 GS-5829 is a BET bromodomain inhibitor, potentially resulting in inhibition of cell growth and apoptotic activity (Blood 2016 128:5104).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02983604 Phase Ib/II Exemestane Fulvestrant + GS-5829 Exemestane + GS-5829 Fulvestrant GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer Terminated
NCT02607228 Phase Ib/II Enzalutamide Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting
NCT02392611 Phase I Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas Completed